GENESIS VECTOR MANUFACTURING SOLUTIONS
Live / Registered — Registered (as of 21 May 2024)
What this means for you
Registered since 21 May 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97705178
- Registration number
- 7393135
- Mark type
- Stylized text
- Filed
- 06 Dec 2022
- Published for opposition
- 31 Oct 2023
- Registered
- 21 May 2024
- Attorney of record
- Joshua M. Gerben, Esq.
Goods and services
- Class 040 — Treatment of materials: Manufacturing services for others in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals, plasmid DNA production; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting
- Class 042 — Scientific and technological services: Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research; research and development in the field of gene therapy acceleration, vector genome copy titers, droplet digital polymerase chain reaction (PCR) and digital polymerase chain reaction (PCR), mass spectrometry, capsid characterization, bioassays, plasmid DNA, and analytics testing in the field of genes and gene therapy
Owner
- CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC, KING OF PRUSSIA, PA, US
- CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC, KING OF PRUSSIA, PA, US
- CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC, KING OF PRUSSIA, PA, US
Prosecution history
- 21 May 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 21 May 2024 — REGISTERED-PRINCIPAL REGISTER
- 18 Apr 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 17 Apr 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 29 Feb 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 06 Feb 2024 — USE AMENDMENT FILED
- 29 Feb 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 06 Feb 2024 — TEAS STATEMENT OF USE RECEIVED
- 26 Dec 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 31 Oct 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 31 Oct 2023 — PUBLISHED FOR OPPOSITION
- 11 Oct 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 20 Sept 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 20 Sept 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 20 Sept 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE